Do analysts rate CSBR or LAB?

Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 96.94%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Standard BioTools 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to CSBR or LAB?

In the previous week, Champions Oncology had 1 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.67 beat Champions Oncology's score of 0.71 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Champions Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Standard BioTools 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend QSI or CSBR?

Quantum-Si currently has a consensus target price of $1.00, indicating a potential upside of 30.55%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum-Si 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CDXS or CSBR?

Codexis currently has a consensus price target of $6.50, suggesting a potential upside of 345.21%. Given Codexis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Codexis is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CDXS or CSBR?

In the previous week, Champions Oncology had 1 more articles in the media than Codexis. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Codexis. Codexis' average media sentiment score of 1.74 beat Champions Oncology's score of 0.71 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Champions Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CSBR or MXCT?

MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 290.63%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MaxCyte 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend QTRX or CSBR?

Quanterix presently has a consensus price target of $3.00, suggesting a potential upside of 11.52%. Given Quanterix's stronger consensus rating and higher probable upside, equities analysts plainly believe Quanterix is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quanterix 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer QTRX or CSBR?

In the previous week, Champions Oncology had 1 more articles in the media than Quanterix. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Quanterix. Quanterix's average media sentiment score of 0.92 beat Champions Oncology's score of 0.71 indicating that Quanterix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Champions Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Champions Oncology (CSBR) Competitors

$5.22 -0.06 (-1.14%)

As of 09/4/2026 04:00 PM Eastern

Compare

CSBR vs. LAB, QSI, CDXS, MXCT, and QTRX

Should you buy Champions Oncology stock or one of its competitors? Champions Oncology's main competitors and comparable companies include Standard BioTools (LAB), Quantum-Si (QSI), Codexis (CDXS), MaxCyte (MXCT), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Champions Oncology compare to Standard BioTools?

Champions Oncology (NASDAQ:CSBR) and Standard BioTools (NASDAQ:LAB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Standard BioTools has a net margin of 100.36% compared to Champions Oncology's net margin of -1.87%. Standard BioTools' return on equity of -7.57% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.87%	-27.48%	-3.84%
Standard BioTools	100.36%	-7.57%	-6.14%

Champions Oncology has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

In the previous week, Champions Oncology had 1 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.67 beat Champions Oncology's score of 0.71 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Champions Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Champions Oncology has higher earnings, but lower revenue than Standard BioTools. Champions Oncology is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.22	-$1.17M	-$0.08	N/A
Standard BioTools	$85.33M	3.15	-$74.90M	$0.22	3.12

Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 96.94%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Standard BioTools beats Champions Oncology on 11 of the 15 factors compared between the two stocks.

How does Champions Oncology compare to Quantum-Si?

Quantum-Si (NASDAQ:QSI) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Quantum-Si currently has a consensus target price of $1.00, indicating a potential upside of 30.55%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Champions Oncology has a net margin of -1.87% compared to Quantum-Si's net margin of -6,138.26%. Champions Oncology's return on equity of -27.48% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,138.26%	-47.12%	-43.18%
Champions Oncology	-1.87%	-27.48%	-3.84%

39.9% of Quantum-Si shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 22.0% of Quantum-Si shares are held by company insiders. Comparatively, 47.0% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Champions Oncology has higher revenue and earnings than Quantum-Si. Champions Oncology is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$2.44M	68.71	-$101.34M	-$0.46	N/A
Champions Oncology	$59.42M	1.22	-$1.17M	-$0.08	N/A

Quantum-Si has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

In the previous week, Champions Oncology had 2 more articles in the media than Quantum-Si. MarketBeat recorded 2 mentions for Champions Oncology and 0 mentions for Quantum-Si. Champions Oncology's average media sentiment score of 0.71 beat Quantum-Si's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum-Si	Neutral
Champions Oncology	Positive

Summary

Champions Oncology beats Quantum-Si on 10 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Codexis?

Codexis (NASDAQ:CDXS) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Champions Oncology has a net margin of -1.87% compared to Codexis' net margin of -39.55%. Champions Oncology's return on equity of -27.48% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Champions Oncology	-1.87%	-27.48%	-3.84%

In the previous week, Champions Oncology had 1 more articles in the media than Codexis. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Codexis. Codexis' average media sentiment score of 1.74 beat Champions Oncology's score of 0.71 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Champions Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Champions Oncology has lower revenue, but higher earnings than Codexis. Champions Oncology is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$77.68M	2.06	-$43.97M	-$0.34	N/A
Champions Oncology	$59.42M	1.22	-$1.17M	-$0.08	N/A

Codexis has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

78.5% of Codexis shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 47.0% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Codexis currently has a consensus price target of $6.50, suggesting a potential upside of 345.21%. Given Codexis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Codexis is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Codexis beats Champions Oncology on 9 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to MaxCyte?

Champions Oncology (NASDAQ:CSBR) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Champions Oncology has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, MaxCyte has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Champions Oncology has a net margin of -1.87% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.87%	-27.48%	-3.84%
MaxCyte	-114.77%	-18.92%	-16.14%

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 47.0% of Champions Oncology shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Champions Oncology had 2 more articles in the media than MaxCyte. MarketBeat recorded 2 mentions for Champions Oncology and 0 mentions for MaxCyte. Champions Oncology's average media sentiment score of 0.71 beat MaxCyte's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Positive
MaxCyte	Neutral

Champions Oncology has higher revenue and earnings than MaxCyte. Champions Oncology is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.22	-$1.17M	-$0.08	N/A
MaxCyte	$33.03M	4.00	-$44.63M	-$0.33	N/A

MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 290.63%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Champions Oncology and MaxCyte tied by winning 8 of the 16 factors compared between the two stocks.

How does Champions Oncology compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Quanterix presently has a consensus price target of $3.00, suggesting a potential upside of 11.52%. Given Quanterix's stronger consensus rating and higher probable upside, equities analysts plainly believe Quanterix is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Champions Oncology has a net margin of -1.87% compared to Quanterix's net margin of -80.25%. Quanterix's return on equity of -26.09% beat Champions Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Champions Oncology	-1.87%	-27.48%	-3.84%

In the previous week, Champions Oncology had 1 more articles in the media than Quanterix. MarketBeat recorded 2 mentions for Champions Oncology and 1 mentions for Quanterix. Quanterix's average media sentiment score of 0.92 beat Champions Oncology's score of 0.71 indicating that Quanterix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Champions Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Champions Oncology has lower revenue, but higher earnings than Quanterix. Champions Oncology is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$153.17M	0.83	-$107.15M	-$2.63	N/A
Champions Oncology	$59.42M	1.22	-$1.17M	-$0.08	N/A

86.5% of Quanterix shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 1.5% of Quanterix shares are owned by insiders. Comparatively, 47.0% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Quanterix has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Summary

Quanterix beats Champions Oncology on 8 of the 15 factors compared between the two stocks.

Get Champions Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSBR vs. The Competition

Export

Metric	Champions Oncology	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$73.49M	$10.02B	$7.26B	$12.90B
Dividend Yield	N/A	1.46%	2.53%	8.90%
P/E Ratio	-65.25	65.01	273.83	25.45
Price / Sales	1.22	111.89	607.44	79.03
Price / Cash	362.98	27.04	77.39	52.28
Price / Book	18.00	35.98	12.85	6.17
Net Income	-$1.17M	$56.67B	$3.49B	$350.08M
7 Day Performance	5.88%	-0.83%	1.04%	-0.14%
1 Month Performance	-1.51%	3.96%	5.52%	1.02%
1 Year Performance	-24.13%	26.47%	24.39%	14.51%

Champions Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CSBR Champions Oncology	0.4459 of 5 stars	$5.22 -1.1%	N/A	-24.5%	$73.49M	$59.42M	N/A	143	News Coverage
LAB Standard BioTools	3.0619 of 5 stars	$0.65 +0.3%	$1.35 +107.1%	-46.9%	$255.18M	$85.33M	2.96	620	News Coverage Positive News
QSI Quantum-Si	2.5694 of 5 stars	$0.79 -6.7%	$1.00 +26.5%	-28.4%	$185.46M	$2.44M	N/A	150
CDXS Codexis	4.0874 of 5 stars	$1.65 -1.8%	$6.50 +293.9%	-39.7%	$183.97M	$70.39M	N/A	250	Positive News Analyst Downgrade
MXCT MaxCyte	2.5559 of 5 stars	$1.31 -3.0%	$5.00 +281.7%	-5.9%	$139.33M	$33.03M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSBR) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Champions Oncology (CSBR) Competitors

CSBR vs. LAB, QSI, CDXS, MXCT, and QTRX

How does Champions Oncology compare to Standard BioTools?

Summary

How does Champions Oncology compare to Quantum-Si?

Summary

How does Champions Oncology compare to Codexis?

Summary

How does Champions Oncology compare to MaxCyte?

Summary

How does Champions Oncology compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Champions Oncology (CSBR) Competitors

CSBR vs. LAB, QSI, CDXS, MXCT, and QTRX

How does Champions Oncology compare to Standard BioTools?

Is CSBR or LAB more profitable?

Which has more risk & volatility, CSBR or LAB?

Does the media refer more to CSBR or LAB?

Which has preferable valuation and earnings, CSBR or LAB?

Do analysts rate CSBR or LAB?

Do insiders & institutionals hold more shares of CSBR or LAB?

Summary

How does Champions Oncology compare to Quantum-Si?

Do analysts recommend QSI or CSBR?

Is QSI or CSBR more profitable?

Do institutionals & insiders believe in QSI or CSBR?

Which has stronger valuation & earnings, QSI or CSBR?

Which has more volatility and risk, QSI or CSBR?

Does the media favor QSI or CSBR?

Summary

How does Champions Oncology compare to Codexis?

Is CDXS or CSBR more profitable?

Does the media prefer CDXS or CSBR?

Which has better earnings & valuation, CDXS or CSBR?

Which has more risk and volatility, CDXS or CSBR?

Do insiders and institutionals have more ownership in CDXS or CSBR?

Do analysts recommend CDXS or CSBR?

Summary

How does Champions Oncology compare to MaxCyte?

Which has more risk and volatility, CSBR or MXCT?

Is CSBR or MXCT more profitable?

Do insiders and institutionals hold more shares of CSBR or MXCT?

Does the media refer more to CSBR or MXCT?

Which has higher earnings & valuation, CSBR or MXCT?

Do analysts recommend CSBR or MXCT?

Summary

How does Champions Oncology compare to Quanterix?

Do analysts recommend QTRX or CSBR?

Is QTRX or CSBR more profitable?

Does the media prefer QTRX or CSBR?

Which has higher valuation and earnings, QTRX or CSBR?

Do insiders and institutionals hold more shares of QTRX or CSBR?

Which has more volatility and risk, QTRX or CSBR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSBR vs. The Competition

Champions Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools